Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer

[1]  C. Liang,et al.  mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer , 2015, Molecular carcinogenesis.

[2]  J. Koivunen,et al.  EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models , 2015, Medical Oncology.

[3]  F. Montemurro,et al.  Linifanib: current status and future potential in cancer therapy , 2015, Expert review of anticancer therapy.

[4]  Yan Zhang,et al.  Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis , 2015, Experimental biology and medicine.

[5]  A. Braun,et al.  Involvement of mTOR signaling pathways in regulating growth and dissemination of metastatic brain tumors via EMT. , 2015, Anticancer research.

[6]  Mingyao Liu,et al.  Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway , 2014, Breast Cancer Research and Treatment.

[7]  A. Barzi,et al.  Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment , 2014, Expert opinion on biological therapy.

[8]  Shibing Deng,et al.  Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer , 2014, Nature Genetics.

[9]  S. Cykert.  A New Paradigm. , 2014, Chest.

[10]  Roopma Wadhwa,et al.  Gastric cancer—molecular and clinical dimensions , 2013, Nature Reviews Clinical Oncology.

[11]  E. Salomone,et al.  HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily , 2013, Oncology letters.

[12]  B. Leber,et al.  A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186 , 2013, Leukemia & lymphoma.

[13]  Pei-Jer Chen,et al.  Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma , 2013, Cancer.

[14]  H. Imamura,et al.  Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer , 2012, Clinical Cancer Research.

[15]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Christensen,et al.  MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells , 2012, Molecular Cancer Therapeutics.

[17]  S. Midorikawa,et al.  [Renal-salt wasting syndrome in a patient with CDDP containing chemotherapy for recurrent non-small-cell lung cancer]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[18]  Ivan Babic,et al.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.

[19]  Holger Gerhardt,et al.  Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.

[20]  Tieliu Shi,et al.  Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis , 2011, Journal of Cancer Research and Clinical Oncology.

[21]  Wei Wang,et al.  The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer , 2011, Clinical Cancer Research.

[22]  Laura H. Tang,et al.  Molecular Classification of Gastric Cancer: A New Paradigm , 2011, Clinical Cancer Research.

[23]  M. Clynes,et al.  Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[25]  Å. Borg,et al.  Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array--comparative genomic hybridization. , 2010, Cancer genetics and cytogenetics.

[26]  P. Catalano,et al.  Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Zhiwei Wang,et al.  Pancreatic cancer stem cells and EMT in drug resistance and metastasis. , 2009, Minerva chirurgica.

[28]  Dong Xu,et al.  Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer , 2009, World Journal of Surgery.

[29]  Mingyao Liu,et al.  Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. , 2009, Cancer research.

[30]  Mingyao Liu,et al.  Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. , 2009, Cancer research.

[31]  K. Glaser,et al.  ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. , 2008, Journal of hepatology.

[32]  Hanry Yu,et al.  In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. , 2008, Leukemia research.

[33]  F. Schmidt.  Meta-Analysis , 2008 .

[34]  K. Glaser,et al.  Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway , 2008, Leukemia.

[35]  Yujia Dai,et al.  ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. , 2007, Blood.

[36]  K. Glaser,et al.  Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. , 2007, Journal of medicinal chemistry.

[37]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[38]  K. Glaser,et al.  Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.

[39]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[40]  D. Dudley,et al.  Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. , 2005, DNA and cell biology.

[41]  A. Donker,et al.  Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function , 2004, Cancer Chemotherapy and Pharmacology.

[42]  J. McCubrey,et al.  EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). , 2003, International journal of oncology.

[43]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[44]  J. Wang,et al.  Cigarette smoke activates caspase-3 to induce apoptosis of human umbilical venous endothelial cells. , 2001, Molecular genetics and metabolism.

[45]  A. Harris,et al.  A phase II study of tomudex (T) in combination with epirubicin (E) and cisplatin (C) in patients with advanced oesophageal and gastric (OG) adenocarcinoma. , 2000 .

[46]  I. Nishisho,et al.  [Efficacy and side effect of continuous intra-arterial infusion of high-dose 5-FU for liver metastases of colorectal cancer]. , 1999, Gan to kagaku ryoho. Cancer & chemotherapy.

[47]  N. Saijo,et al.  [Effect of cisplatin on cell cycle regulators]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.